USPTO serial 99323813
A
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 29, 2026
- Examiner
- LAVACHE, LINDA M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with A?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Abbott Park, IL, US
Abbott Park, IL, US
Abbott Park, IL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michele H. Bowman
Michele H. Bowman Abbott Laboratories100 Abbott Park RoadAbbott Park, IL 60064United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical diagnostic instruments for diabetes diagnosis and monitoring; medical diagnostic instruments for analyzing, measuring and testing blood, bodily fluids and tissue; medical diagnostic instruments for in vitro diagnostic testing and analysis, namely, sample handlers, sample preparation equipment, equipment for testing bodily fluids for medical diagnosis; medical diagnostic instruments for microbial screening and identification, analysis of nucleic acid sequences, nucleic acids, genetic materials, infectious agents and pathogens; medical and surgical apparatus and instruments, namely, stents, catheters, guide wires, bioabsorbable stents, drug-eluting stents, drug-eluting resorbable scaffolding of artificial materials for use with catheters and stents for use in vascular procedures; medical apparatus and equipment, namely, patient monitor that is for use in electronic acquisition, capture and transmission of medical device status and patient medical and physiological data used in connection with implantable cardiac devices, and external or implantable cardiac therapeutic or diagnostic devices; medical diagnostic instruments for testing patients for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic apparatus and incorporated recorded computer software for analyzing medical data and informing treatment decisions in connection with cardiology conditions, chronic pain conditions, movement disorder conditions, and procedures all sold as a unit, for medical diagnostic use; medical apparatus and instruments, namely, blood glucose meters, blood ketone meters, biosensors and biosensor applicators for measuring blood glucose, blood ketone, and blood lactate levels, electrochemical sensors for measuring analyte concentrations in interstitial fluid, electrochemical sensors for monitoring analyte levels in interstitial fluid, electrochemical sensors for monitoring analyte concentrations in bodily fluids, electrochemical sensors for monitoring analyte levels in bodily fluids, electrochemical sensors for monitoring analytes in bodily fluids, needles for injecting insulin, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, and insulin pumps; blood, bodily fluid, tissue, and fecal matter medical testing instruments; medical apparatus for monitoring, tracking, and determining analyte concentrations; sensors for monitoring, tracking, and determining analyte concentrations for medical and health purposes; medical apparatus and instruments for monitoring glucose levels; medical apparatus and instruments for monitoring ketones; medical instruments and apparatus for monitoring glucose for health purposes; medical instruments and apparatus for monitoring ketones for health purposes; patient monitoring sensors for monitoring glucose concentrations; patient monitoring sensors for monitoring ketone concentrations; sensor-based glucose monitors for medical purposes; sensor-based ketone monitors for medical purposes; medical devices, namely, catheters and catheter interface modules; medical and surgical catheters; enteral nutritional delivery system, comprised of enteral feeding tubes; breastmilk storage bottle; infant formula storage bottle, sold empty; baby bottles; baby nursers; medical and surgical apparatus and instruments, namely, implantable cardiac devices in the nature of pacemakers, implantable cardioverter defibrillators (ICDs), and pulse generators for cardiac rhythm management; medical stimulation leads for cardiac rhythm management; implantable heart monitors; neurostimulators, namely, implantable systems comprised of cannulas, surgical tunneling tools, medical device leads in the nature of pulse generator leads, torque wrenches, electronic controllers, power adapters, and recorded medical device operating software and firmware, all for implantation and operation of neural tissue stimulators and all sold together as a unit for medical use designed to treat chronic pain and movement disorders; telemetry systems for device communication comprised of remote telemetry devices for medical purposes used to monitor and manage implanted medical devices across cardiac and neurological therapies; electrophysiology systems comprised primarily of medical sensors for detecting and measuring electrical activity in the body, and electronic nerve stimulators for medical use, and also including amplifiers and recorded operating software therefor, all sold as a unit; catheter-based technologies, namely, balloon dilatation catheters, ablation catheters, mapping catheters, steerable catheters, introducer kits designed for vascular access during diagnostic and interventional cardiovascular procedures comprised of medical guide wires and stent delivery systems; vascular tools for medical use, namely, drug-eluting and self-expandable stents, occlusion and filtration devices for temporary medical use during interventional procedures to capture debris in blood, thrombectomy systems comprised of catheters, suction tubing for use with catheters, and guide wires for treating blood clots, and embolic protection devices for filtering debris during vascular procedures; heart assist devices, namely, ventricular assist devices, catheter pumps, percutaneous heart pumps, blood pumps, and cannula kits comprised of cannulas, inner catheters, and subselection catheters; prosthetic heart valves, annuloplasty rings and cuffs; surgical instruments and apparatus including coring knives, slitting tools, sewing rings, anastomotic devices, sizers, tunnelers, hand pumping bulbs, and stabilization belts; medical instruments, namely, arterial closure devices; oxygenators for medical use; perfusion tubing for medical use; braided intravascular sheaths for medical use; medical apparatus, namely, bleed back control valves comprised of artificial materials; delivery catheters; wearable external components for heart assist devices, namely, computer display monitors used in direct association with cardiac rhythm management; medical imaging and navigation systems comprised of medical ultrasound imaging apparatus and medical optical coherence tomography apparatus for 2D and 3D localization of medical images; diagnostic apparatus for the medical analysis of bodily fluids and tissue; cartridges, sold empty, for use in portable clinical blood analyzers for medical use; medical specimen collection kit, consisting of medical diagnostic instruments for the analysis of bodily fluids and tissue; microbial tubes for blood testing; blood testing apparatus; electronic cartridges, sold empty, for use in portable clinical blood analyzers; diagnostic apparatus for medical purposes, namely, for diagnosing pregnancy, fertility, and infectious diseases; medical diagnostic apparatus and instruments for detecting the presence and measuring the level of drugs and alcohol in blood and other body fluids; medical apparatus and instruments for the screening of drugs and alcohol, namely, medical diagnostic devices for analyzing blood and other bodily fluids for the presence of drugs and alcohol; medical instruments, namely, self-processing diagnostic instrument for processing of test cartridges containing chemical reagents for in-vitro diagnostic medical testing; medical devices, namely, camera-based instruments for reading and interpreting lateral flow assays for medical diagnostic and treatment purposes; medical devices, namely, camera-based instruments for reading and interpreting in vitro diagnostic tests for influenza, strep, pneumonia, and legionella; medical diagnostic instruments and replacement parts therefor for molecular diagnostic analysis of infectious disease; medical diagnostic analyzers and replacement parts therefor for detecting and managing infectious diseases; medical apparatus for determining and analyzing in vitro molecular interactions; medical apparatus for analyzing molecules, cells, tissues and organisms for detecting and managing infectious diseases; medical apparatus for analyzing nucleic acid and proteins for diagnosis and testing of infectious diseases; medical instruments used for blood, bodily fluid and tissue testing; nucleic acid medical testing instruments for diagnosis and management of infectious diseases; medical diagnostic instruments for detection of infectious diseases; hematology analyzers for medical diagnostic use; clinical chemistry analyzers for medical diagnostic use in testing bodily fluids; immunoassay analyzers for medical diagnostic use; blood screening instruments for medical use; medical diagnostic instruments for in vitro diagnostic testing and analysis of blood, urine, and other body fluids for infectious diseases, biomarkers, and chemical imbalances; molecular diagnostic instruments for the analysis of body fluids for medical purposes; medical diagnostic instruments, namely, sample handlers, sample preparation equipment, equipment for testing bodily fluids for medical diagnosis; specimen collection kits used in connection with in vitro diagnostics comprised of sample collection tubes, test bases for adapted holding sample collection tubes, sterile medical swabs, transfer pipettes, medical diagnostic extraction reagents, control swabs for medical use, printed instruction sheets in the field of medical specimen collection and testing, and plastic mailing tubes; blood analyzing instruments for medical diagnostic purposes; medical diagnostic analyzers for measuring, testing and analyzing body fluids; cartridges, sold empty, chambers and chamber trays for medical use in medical diagnostic blood analyzers, medical diagnostic hematology analyzers, and medical diagnostic analyzers for measuring, testing and analyzing body fluids | ACTIVE | Aug 30, 1982 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 29, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 11, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 11, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 5, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 14, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 14, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 14, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 14, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 14, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 16, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 16, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 16, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 21, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 21, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 21, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 24, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 24, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 24, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 11, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 11, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 12, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 5, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 6, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 6, 2025 | NWAP | NEW APPLICATION ENTERED | — |